Search Results - "Søgaard, Ole S."

Camostat mesylate against SARS‐CoV‐2 and COVID‐19—Rationale, dosing and safety by Breining, Peter, Frølund, Anne Lier, Højen, Jesper Falkesgaard, Gunst, Jesper Damsgaard, Staerke, Nina B., Saedder, Eva, Cases‐Thomas, Manuel, Little, Paul, Nielsen, Lars Peter, Søgaard, Ole S., Kjolby, Mads

“…The coronavirus responsible for COVID‐19, SARS‐CoV‐2, utilizes a viral membrane spike protein for host cell entry. For the virus to engage in host membrane…”
Get full text

The Depsipeptide Romidepsin Reverses HIV-1 Latency In Vivo by Søgaard, Ole S, Graversen, Mette E, Leth, Steffen, Olesen, Rikke, Brinkmann, Christel R, Nissen, Sara K, Kjaer, Anne Sofie, Schleimann, Mariane H, Denton, Paul W, Hey-Cunningham, William J, Koelsch, Kersten K, Pantaleo, Giuseppe, Krogsgaard, Kim, Sommerfelt, Maja, Fromentin, Remi, Chomont, Nicolas, Rasmussen, Thomas A, Østergaard, Lars, Tolstrup, Martin

“…Pharmacologically-induced activation of replication competent proviruses from latency in the presence of antiretroviral treatment (ART) has been proposed as a…”
Get full text

Inflammation and Platelet Activation After COVID-19 Vaccines - Possible Mechanisms Behind Vaccine-Induced Immune Thrombocytopenia and Thrombosis by Ostrowski, Sisse R, Søgaard, Ole S, Tolstrup, Martin, Stærke, Nina B, Lundgren, Jens, Østergaard, Lars, Hvas, Anne-Mette

“…Introduction of vaccines against COVID-19 has provided the most promising chance to control the world-wide COVID-19 pandemic. However, the adenovirus-vector…”
Get full text

Camostat mesylate inhibits SARS-CoV-2 activation by TMPRSS2-related proteases and its metabolite GBPA exerts antiviral activity by Hoffmann, Markus, Hofmann-Winkler, Heike, Smith, Joan C., Krüger, Nadine, Arora, Prerna, Sørensen, Lambert K., Søgaard, Ole S., Hasselstrøm, Jørgen Bo, Winkler, Michael, Hempel, Tim, Raich, Lluís, Olsson, Simon, Danov, Olga, Jonigk, Danny, Yamazoe, Takashi, Yamatsuta, Katsura, Mizuno, Hirotaka, Ludwig, Stephan, Noé, Frank, Kjolby, Mads, Braun, Armin, Sheltzer, Jason M., Pöhlmann, Stefan

“…Antivirals are needed to combat the COVID-19 pandemic, which is caused by SARS-CoV-2. The clinically-proven protease inhibitor Camostat mesylate inhibits…”
Get full text

Panobinostat, a histone deacetylase inhibitor, for latent-virus reactivation in HIV-infected patients on suppressive antiretroviral therapy: a phase 1/2, single group, clinical trial by Rasmussen, Thomas A, Dr, Tolstrup, Martin, PhD, Brinkmann, Christel R, PhD, Olesen, Rikke, PhD, Erikstrup, Christian, MD, Solomon, Ajantha, Winckelmann, Anni, Palmer, Sarah, PhD, Dinarello, Charles, Prof, Buzon, Maria, PhD, Lichterfeld, Mathias, MD, Lewin, Sharon R, Prof, Østergaard, Lars, Prof, Søgaard, Ole S, MD

“…Summary Background Activating the expression of latent virus is an approach that might form part of an HIV cure. We assessed the ability of the histone…”
Get full text

Effects of 24-week Toll-like receptor 9 agonist treatment in HIV type 1+ individuals by Vibholm, Line K, Konrad, Christina V, Schleimann, Mariane H, Frattari, Giacomo, Winckelmann, Anni, Klastrup, Vibeke, Jensen, Nanna M, Jensen, Sanne S, Schmidt, Manuel, Wittig, Burghardt, Zuwala, Kaja, Mack, Katharina, Olesen, Rikke, Hua, Stephane, Lichterfeld, Mathias, Østergaard, Lars, Denton, Paul W, Tolstrup, Martin, Søgaard, Ole S

“…DESIGN:This was an exploratory, single-arm clinical trial that tested the immune enhancement effects of 24-weeks of Toll-like receptor 9 (TLR9) agonist…”
Get full text

Administration of broadly neutralizing anti-HIV-1 antibodies at ART initiation maintains long-term CD8+ T cell immunity by Rosás-Umbert, Miriam, Gunst, Jesper D., Pahus, Marie H., Olesen, Rikke, Schleimann, Mariane, Denton, Paul W., Ramos, Victor, Ward, Adam, Kinloch, Natalie N., Copertino, Dennis C., Escribà, Tuixent, Llano, Anuska, Brumme, Zabrina L., Brad Jones, R., Mothe, Beatriz, Brander, Christian, Fox, Julie, Nussenzweig, Michel C., Fidler, Sarah, Caskey, Marina, Tolstrup, Martin, Søgaard, Ole S.

“…In simian-human immunodeficiency virus (SHIV)-infected non-human primates, broadly neutralizing antibodies (bNAbs) against the virus appear to stimulate T cell…”
Get full text

Characterization of the HIV-1 transcription profile after romidepsin administration in ART-suppressed individuals by Moron-Lopez, Sara, Kim, Peggy, Søgaard, Ole S, Tolstrup, Martin, Wong, Joseph K, Yukl, Steven A

“…OBJECTIVES:Reversing HIV-1 latency has been suggested as a strategy to eradicate HIV-1. We investigated the effect of romidepsin on the HIV transcription…”
Get full text

SARS-CoV-2 persistence is associated with antigen-specific CD8 T-cell responses by Vibholm, Line K., Nielsen, Stine S.F., Pahus, Marie H., Frattari, Giacomo S., Olesen, Rikke, Andersen, Rebecca, Monrad, Ida, Andersen, Anna H.F., Thomsen, Michelle M., Konrad, Christina V., Andersen, Sidsel D., Højen, Jesper F., Gunst, Jesper D., Østergaard, Lars, Søgaard, Ole S., Schleimann, Mariane H., Tolstrup, Martin

“…Upon SARS-CoV-2 infection, most individuals develop neutralizing antibodies and T-cell immunity. However, some individuals reportedly remain SARS-CoV-2 PCR…”
Get full text

Short-Course Toll-Like Receptor 9 Agonist Treatment Impacts Innate Immunity and Plasma Viremia in Individuals With Human Immunodeficiency Virus Infection by Vibholm, Line, Schleimann, Mariane H., Højen, Jesper F., Benfield, Thomas, Offersen, Rasmus, Rasmussen, Katrine, Olesen, Rikke, Dige, Anders, Agnholt, Jørgen, Grau, Judith, Buzon, Maria, Wittig, Burghardt, Lichterfeld, Mathias, Petersen, Andreas Munk, Deng, Xutao, Abdel-Mohsen, Mohamed, Pillai, Satish K., Rutsaert, Sofie, Trypsteen, Wim, De Spiegelaere, Ward, Vandekerchove, Linos, Østergaard, Lars, Rasmussen, Thomas A., Denton, Paul W., Tolstrup, Martin, Søgaard, Ole S.

“…Background. Treatment with latency reversing agents (LRAs) enhances human immunodeficiency virus type 1 (HIV-1) transcription in vivo but leads to only modest…”
Get full text

TLR2 and TLR7 mediate distinct immunopathological and antiviral plasmacytoid dendritic cell responses to SARS‐CoV‐2 infection by van der Sluis, Renée M, Cham, Lamin B, Gris‐Oliver, Albert, Gammelgaard, Kristine R, Pedersen, Jesper G, Idorn, Manja, Ahmadov, Ulvi, Hernandez, Sabina Sanches, Cémalovic, Ena, Godsk, Stine H, Thyrsted, Jacob, Gunst, Jesper D, Nielsen, Silke D, Jørgensen, Janni J, Bjerg, Tobias Wang, Laustsen, Anders, Reinert, Line S, Olagnier, David, Bak, Rasmus O, Kjolby, Mads, Holm, Christian K, Tolstrup, Martin, Paludan, Søren R, Kristensen, Lasse S, Søgaard, Ole S, Jakobsen, Martin R

“…Understanding the molecular pathways driving the acute antiviral and inflammatory response to SARS‐CoV‐2 infection is critical for developing treatments for…”
Get full text

Early intervention with 3BNC117 and romidepsin at antiretroviral treatment initiation in people with HIV-1: a phase 1b/2a, randomized trial by Gunst, Jesper D., Pahus, Marie H., Rosás-Umbert, Miriam, Lu, I-Na, Benfield, Thomas, Nielsen, Henrik, Johansen, Isik S., Mohey, Rajesh, Østergaard, Lars, Klastrup, Vibeke, Khan, Maryam, Schleimann, Mariane H., Olesen, Rikke, Støvring, Henrik, Denton, Paul W., Kinloch, Natalie N., Copertino, Dennis C., Ward, Adam R., Alberto, Winiffer D. Conce, Nielsen, Silke D., Puertas, Maria C., Ramos, Victor, Reeves, Jacqueline D., Petropoulos, Christos J., Martinez-Picado, Javier, Brumme, Zabrina L., Jones, R. Brad, Fox, Julie, Tolstrup, Martin, Nussenzweig, Michel C., Caskey, Marina, Fidler, Sarah, Søgaard, Ole S.

“…Attempts to reduce the human immunodeficiency virus type 1 (HIV-1) reservoir and induce antiretroviral therapy (ART)-free virologic control have largely been…”
Get full text

Romidepsin-induced HIV-1 viremia during effective antiretroviral therapy contains identical viral sequences with few deleterious mutations by Winckelmann, Anni, Barton, Kirston, Hiener, Bonnie, Schlub, Timothy E, Shao, Wei, Rasmussen, Thomas A, Østergaard, Lars, Søgaard, Ole S, Tolstrup, Martin, Palmer, Sarah

“…To investigate the origin of the HIV-1 viremia induced by the latency-reversing agent romidepsin. Six individuals on suppressive antiretroviral therapy…”
Get full text

HIV Reactivation from Latency after Treatment Interruption Occurs on Average Every 5-8 Days--Implications for HIV Remission by Pinkevych, Mykola, Cromer, Deborah, Tolstrup, Martin, Grimm, Andrew J, Cooper, David A, Lewin, Sharon R, Søgaard, Ole S, Rasmussen, Thomas A, Kent, Stephen J, Kelleher, Anthony D, Davenport, Miles P

“…HIV infection can be effectively controlled by anti-retroviral therapy (ART) in most patients. However therapy must be continued for life, because interruption…”
Get full text

Impacts of HIV Cure Interventions on Viral Reservoirs in Tissues by Denton, Paul W, Søgaard, Ole S, Tolstrup, Martin

“…HIV reservoirs persist in infected individuals despite combination antiretroviral therapy and can be identified in secondary lymphoid tissues, in intestinal…”
Get full text

Deciphering the association between HIV-specific immunity and immune reconstitution by Søgaard, Ole S.

Get full text

Innate Immune Activity Correlates with CD4 T Cell-Associated HIV-1 DNA Decline during Latency-Reversing Treatment with Panobinostat by Olesen, Rikke, Vigano, Selena, Rasmussen, Thomas A, Søgaard, Ole S, Ouyang, Zhengyu, Buzon, Maria, Bashirova, Arman, Carrington, Mary, Palmer, Sarah, Brinkmann, Christel R, Yu, Xu G, Østergaard, Lars, Tolstrup, Martin, Lichterfeld, Mathias

“…The pharmaceutical reactivation of dormant HIV-1 proviruses by histone deacetylase inhibitors (HDACi) represents a possible strategy to reduce the reservoir of…”
Get full text

Characterization of Intact Proviruses in Blood and Lymph Node from HIV-Infected Individuals Undergoing Analytical Treatment Interruption by Vibholm, Line K, Lorenzi, Julio C C, Pai, Joy A, Cohen, Yehuda Z, Oliveira, Thiago Y, Barton, John P, Garcia Noceda, Marco, Lu, Ching-Lan, Ablanedo-Terrazas, Yuria, Del Rio Estrada, Perla M, Reyes-Teran, Gustavo, Tolstrup, Martin, Denton, Paul W, Damsgaard, Tine, Søgaard, Ole S, Nussenzweig, Michel C

“…The role of lymphoid tissue as a potential source of HIV-1 rebound following interruption of antiretroviral therapy (ART) is uncertain. To address this issue,…”
Get full text

SARS-CoV-2 elicits robust adaptive immune responses regardless of disease severity by Nielsen, Stine SF, Vibholm, Line K, Monrad, Ida, Olesen, Rikke, Frattari, Giacomo S, Pahus, Marie H, Højen, Jesper F, Gunst, Jesper D, Erikstrup, Christian, Holleufer, Andreas, Hartmann, Rune, Østergaard, Lars, Søgaard, Ole S, Schleimann, Mariane H, Tolstrup, Martin

“…The SARS-CoV-2 pandemic currently prevails worldwide. To understand the immunological signature of SARS-CoV-2 infections and aid the search and evaluation of…”
Get full text

Recommendations for analytical antiretroviral treatment interruptions in HIV research trials—report of a consensus meeting by Julg, Boris, Dee, Lynda, Ananworanich, Jintanat, Barouch, Dan H, Bar, Katharine, Caskey, Marina, Colby, Donn J, Dawson, Liza, Dong, Krista L, Dubé, Karine, Eron, Joseph, Frater, John, Gandhi, Rajesh T, Geleziunas, Romas, Goulder, Philip, Hanna, George J, Jefferys, Richard, Johnston, Rowena, Kuritzkes, Daniel, Li, Jonathan Z, Likhitwonnawut, Udom, van Lunzen, Jan, Martinez-Picado, Javier, Miller, Veronica, Montaner, Luis J, Nixon, Douglas F, Palm, David, Pantaleo, Giuseppe, Peay, Holly, Persaud, Deborah, Salzwedel, Jessica, Salzwedel, Karl, Schacker, Timothy, Sheikh, Virginia, Søgaard, Ole S., Spudich, Serena, Stephenson, Kathryn, Sugarman, Jeremy, Taylor, Jeff, Tebas, Pablo, Tiemessen, Caroline T, Tressler, Randall, Weiss, Carol D, Zheng, Lu, Robb, Merlin L, Michael, Nelson L, Mellors, John W, Deeks, Steven G, Walker, Bruce D

“…Analytical antiretroviral treatment interruption (ATI) is an important feature of HIV research, seeking to achieve sustained viral suppression in the absence…”
Get full text